Research Reports Initiation on Biotech Stocks -- Epizyme, Sierra Oncology, Five Prime Therapeutics, and AveXis

Tuesday, April 11, 2017 Research News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, April 11, 2017 /PRNewswire/ --

On Monday, April 10, 2017, US markets saw

broad based gains with six out of nine sectors finishing the trading sessions in green. Major US indices were also bullish at the close of yesterday's session. The NASDAQ Composite ended the day at 5,880.93, up 0.05%; the Dow Jones Industrial Average
edged 0.01% higher, to finish at 20,658.02; and the S&P 500 closed at 2,357.16, up 0.07%. This Tuesday morning, looks at the performance of these four Biotechnology stocks: Epizyme Inc. (NASDAQ: EPZM), Sierra Oncology Inc. (NASDAQ: SRRA), Five Prime Therapeutics Inc. (NASDAQ: FPRX), and AveXis Inc. (NASDAQ: AVXS). You can access our complimentary research reports on these stocks now at:


Cambridge, Massachusetts headquartered Epizyme Inc.'s stock finished Monday's session 0.34% lower at $14.60, with a total volume of 168,787 shares traded. Over the last three months and the previous one year, Epizyme's shares have gained 22.18% and 20.16%, respectively. The Company's shares are trading above its 50-day and 200-day moving averages by 2.16% and 32.42%, respectively. Shares of Epizyme, which discovers and develops novel epigenetic therapies for patients with cancer and other diseases in the US, have a Relative Strength Index (RSI) of 37.84. Visit us today and download your complete report on EPZM for free at:

Sierra Oncology 

Vancouver, Canada headquartered Sierra Oncology Inc.'s stock closed the day flat at $1.43. The stock recorded a trading volume of 208,333 shares. Sierra Oncology's shares are trading 1.64% and 13.65% below its 50-day and 200-day moving averages, respectively. Additionally, shares of the Company, which engages in developing DNA Damage Response therapeutics for the treatment of patients with cancer, have an RSI of 44.91. The complimentary research report on SRRA can be accessed at:

Five Prime Therapeutics  

On Monday, shares in San Francisco, California headquartered Five Prime Therapeutics Inc. ended the session 2.92% higher at $33.84, with a total volume of 541,168 shares traded. Five Prime Therapeutics' shares are trading 19.13% below its 50-day moving average and 28.83% below its 200-day moving average. Moreover, shares of the Company, which focuses on the discovery and development of immuno-oncology protein therapeutics in the US, have an RSI of 31.91. Register for free on and download the PDF research report on FPRX at:


On Monday, shares in Bannockburn, Illinois headquartered AveXis Inc. recorded a trading volume of 325,113 shares. The stock ended the day 1.54% lower at $68.40. AveXis' stock has surged 22.76% in the last three months and 193.81% in the previous one year. The Company's shares are trading above its 50-day and 200-day moving averages by 3.21% and 33.58%, respectively. Furthermore, shares of AveXis, which engages in developing and commercializing treatments for patients suffering from rare and life-threatening neurological genetic diseases, have an RSI of 42.49.

On March 30th, 2017, research firm UBS initiated a 'Buy' rating on the Company's stock, with a target price of $95 per share. Get free access to your research report on AVXS at:

Stock Callers: 

Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

SC has not been compensated; directly or indirectly; for producing or publishing this document. 


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  


SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: Phone number: +44-330-808-3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Chelmsford Park SA


Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store